Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRXM NASDAQ:CUR NASDAQ:IPHA OTCMKTS:MYMX OTCMKTS:OMBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRXMCardium Therapeutics$0.00$0.00▼$0.00N/AN/AN/AN/ACURNeuralstem$1.87-2.1%$1.06$1.10▼$13.78$3.93M1.81236,278 shs1.84 million shsIPHAInnate Pharma$1.79$1.70$1.17▼$2.63$168.12M0.3138,096 shs10,509 shsMYMXMymetics$0.00$0.00$0.00▼$0.00N/A2.13N/AN/AOMBPOmni Bio Pharmaceutical$0.00$0.00$0.00▼$0.04N/AN/AN/AN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRXMCardium Therapeutics0.00%0.00%0.00%0.00%0.00%CURNeuralstem0.00%0.00%0.00%-6.50%+152.91%IPHAInnate Pharma0.00%-1.10%+2.29%+37.69%-1.38%MYMXMymetics0.00%0.00%0.00%0.00%0.00%OMBPOmni Bio Pharmaceutical0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRXMCardium Therapeutics$0.00$0.00▼$0.00N/AN/AN/AN/ACURNeuralstem$1.87-2.1%$1.06$1.10▼$13.78$3.93M1.81236,278 shs1.84 million shsIPHAInnate Pharma$1.79$1.70$1.17▼$2.63$168.12M0.3138,096 shs10,509 shsMYMXMymetics$0.00$0.00$0.00▼$0.00N/A2.13N/AN/AOMBPOmni Bio Pharmaceutical$0.00$0.00$0.00▼$0.04N/AN/AN/AN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRXMCardium Therapeutics0.00%0.00%0.00%0.00%0.00%CURNeuralstem0.00%0.00%0.00%-6.50%+152.91%IPHAInnate Pharma0.00%-1.10%+2.29%+37.69%-1.38%MYMXMymetics0.00%0.00%0.00%0.00%0.00%OMBPOmni Bio Pharmaceutical0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRXMCardium Therapeutics 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/AIPHAInnate Pharma 2.50Moderate Buy$5.00179.33% UpsideMYMXMymetics 0.00N/AN/AN/AOMBPOmni Bio Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IPHA, MYMX, OMBP, CUR, and CRXM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026IPHAInnate Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRXMCardium TherapeuticsN/AN/AN/AN/AN/AN/ACURNeuralstem$260K15.10N/AN/A$6.64 per share0.28IPHAInnate Pharma$2.79M60.32N/AN/A($0.26) per share-6.88MYMXMymeticsN/AN/AN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRXMCardium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstem-$4.93MN/AN/AN/AN/A-39,417.64%-170.51%-110.16%N/AIPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/AMYMXMymeticsN/A-$20.00N/AN/AN/AN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRXMCardium TherapeuticsN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AMYMXMymeticsN/AN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRXMCardium TherapeuticsN/AN/AN/ACURNeuralstemN/A2.532.53IPHAInnate PharmaN/A1.271.27MYMXMymeticsN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRXMCardium TherapeuticsN/ACURNeuralstem38.30%IPHAInnate Pharma0.16%MYMXMymetics0.73%OMBPOmni Bio PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipCRXMCardium Therapeutics49.80%CURNeuralstem5.38%IPHAInnate Pharma31.89%MYMXMymetics5.13%OMBPOmni Bio PharmaceuticalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRXMCardium Therapeutics3N/AN/ANot OptionableCURNeuralstem62.10 millionN/ANot OptionableIPHAInnate Pharma22093.92 million63.97 millionNot OptionableMYMXMymetics8150,000144,000Not OptionableOMBPOmni Bio Pharmaceutical1N/AN/ANot OptionableIPHA, MYMX, OMBP, CUR, and CRXM HeadlinesRecent News About These CompaniesHow AI and omnichannel are transforming pharma marketingOctober 23, 2024 | pharmaphorum.comPEmphasizing Bio-Pharmaceutical CMC Residue Quality ControlApril 18, 2024 | technologynetworks.comTZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class AMarch 2, 2024 | morningstar.comMShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)December 2, 2023 | investing.comShanxi Jinbo Bio pharmaceutical Co Ltd 832982November 12, 2023 | morningstar.comMOversold Conditions For BridgeBio Pharma (BBIO)October 6, 2023 | nasdaq.comSinopep Allsino Bio Pharmaceutical Co Ltd Class AAugust 24, 2023 | morningstar.comMOmni-CrawlerJune 29, 2023 | hackaday.comHShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.May 16, 2023 | wsj.com2023 Bio Pharma Logistics Market | Dynamic Report By 2030April 21, 2023 | marketwatch.comShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Class HApril 21, 2023 | morningstar.comMBio-pharma Market Key Players and Forecast till 2031March 31, 2023 | marketwatch.com2023 Bio Pharma Logistics Market Size, Growth | Global Industry Trends [2029]March 29, 2023 | marketwatch.comMy Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare ConferenceMarch 25, 2023 | thestreet.comZhejiang Wolwo Bio Pharmaceutical Co. Ltd.March 22, 2023 | wsj.comSanofi’s $2.9B deal for Provention Bio to bolster diabetes treatment offeringsMarch 13, 2023 | mmm-online.comMZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A 300357 Stock QuoteFebruary 21, 2023 | morningstar.comMBio Pharma Logistics Market [Latest Report ]2023 is Booming with Figures, Sales Volume, Financial Barriers and Outlook to 2027January 27, 2023 | marketwatch.comBioMarin PharmaceuticalJanuary 5, 2023 | forbes.comZhejiang Wolwo Bio-Pharmaceutical Co LtdOctober 7, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingBy Jessica Mitacek | June 4, 2026IREN's 800MW Bet Flips the AI Power SwitchBy Jeffrey Neal Johnson | June 6, 2026CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?By Chris Markoch | June 6, 2026IPHA, MYMX, OMBP, CUR, and CRXM Company DescriptionsCardium Therapeutics OTCMKTS:CRXMGene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Innate Pharma NASDAQ:IPHA$1.79 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.34%) As of 06/26/2026 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Mymetics OTCMKTS:MYMX$0.0003 0.00 (0.00%) As of 06/25/2026Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.Omni Bio Pharmaceutical OTCMKTS:OMBP$0.0010 0.00 (0.00%) As of 08/18/2020Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
